Gujarat Kidney & Super Speciality Ltd
Incorporated in 2019, Gujarat Kidney and Super Speciality Limited specializes in providing multispeciality healthcare services.[1]
- Market Cap ₹ 1,154 Cr.
- Current Price ₹ 146
- High / Low ₹ 147 / 98.2
- Stock P/E 117
- Book Value ₹ 4.25
- Dividend Yield 0.00 %
- ROCE 51.5 %
- ROE 51.2 %
- Face Value ₹ 2.00
Pros
- Company has a good return on equity (ROE) track record: 3 Years ROE 43.5%
- Debtor days have improved from 229 to 138 days.
Cons
- Stock is trading at 33.5 times its book value
- Though the company is reporting repeated profits, it is not paying out dividend
- Company might be capitalizing the interest cost
* The pros and cons are machine generated. Pros / cons are based on a checklist to highlight important points. Please exercise caution and do your own analysis.
Peer comparison
Healthcare Healthcare Healthcare Services Hospital
Part of BSE Healthcare BSE IPO Nifty IPO
Quarterly Results
Consolidated Figures in Rs. Crores / View Standalone
Profit & Loss
Consolidated Figures in Rs. Crores / View Standalone
| Mar 2023 | Mar 2024 | Mar 2025 | |
|---|---|---|---|
| 0.00 | 4.77 | 40.24 | |
| 0.01 | 2.81 | 23.68 | |
| Operating Profit | -0.01 | 1.96 | 16.56 |
| OPM % | 41.09% | 41.15% | |
| 0.00 | 0.70 | 0.15 | |
| Interest | 0.00 | 0.07 | 0.65 |
| Depreciation | 0.00 | 0.32 | 3.29 |
| Profit before tax | -0.01 | 2.27 | 12.77 |
| Tax % | 0.00% | 24.67% | 25.53% |
| -0.01 | 1.71 | 9.50 | |
| EPS in Rs | -0.50 | 85.50 | 1.66 |
| Dividend Payout % | 0.00% | 0.00% | 0.00% |
| Compounded Sales Growth | |
|---|---|
| 10 Years: | % |
| 5 Years: | % |
| 3 Years: | % |
| TTM: | 744% |
| Compounded Profit Growth | |
|---|---|
| 10 Years: | % |
| 5 Years: | % |
| 3 Years: | % |
| TTM: | 697% |
| Stock Price CAGR | |
|---|---|
| 10 Years: | % |
| 5 Years: | % |
| 3 Years: | % |
| 1 Year: | % |
| Return on Equity | |
|---|---|
| 10 Years: | % |
| 5 Years: | % |
| 3 Years: | 43% |
| Last Year: | 51% |
Balance Sheet
Consolidated Figures in Rs. Crores / View Standalone
| Mar 2023 | Mar 2024 | Mar 2025 | Sep 2025 | |
|---|---|---|---|---|
| Equity Capital | 0.20 | 0.20 | 11.37 | 11.37 |
| Reserves | 0.17 | 10.60 | 14.57 | 22.13 |
| 0.00 | 5.86 | 8.31 | 19.53 | |
| 3.50 | 3.86 | 21.09 | 22.65 | |
| Total Liabilities | 3.87 | 20.52 | 55.34 | 75.68 |
| 0.00 | 13.64 | 31.01 | 29.43 | |
| CWIP | 0.00 | 0.00 | 0.00 | 0.00 |
| Investments | 0.00 | 0.00 | 0.00 | 0.00 |
| 3.87 | 6.88 | 24.33 | 46.25 | |
| Total Assets | 3.87 | 20.52 | 55.34 | 75.68 |
Cash Flows
Consolidated Figures in Rs. Crores / View Standalone
| Mar 2023 | Mar 2024 | Mar 2025 | |
|---|---|---|---|
| 0.00 | 1.21 | 13.61 | |
| 0.00 | 0.22 | -18.14 | |
| 0.00 | -0.47 | 6.16 | |
| Net Cash Flow | 0.00 | 0.97 | 1.63 |
| Free Cash Flow | 0.00 | 1.64 | -4.64 |
| CFO/OP | 0% | 70% | 99% |
Ratios
Consolidated Figures in Rs. Crores / View Standalone
| Mar 2023 | Mar 2024 | Mar 2025 | |
|---|---|---|---|
| Debtor Days | 321.38 | 137.51 | |
| Inventory Days | |||
| Days Payable | |||
| Cash Conversion Cycle | 321.38 | 137.51 | |
| Working Capital Days | 100.24 | -24.13 | |
| ROCE % | 19.26% | 51.52% |
Insights
In beta| Mar 2026 | |
|---|---|
| Acquired Ownership Stake - Ashwini Medical Centre % ・Standalone data |
|
| Acquired Ownership Stake - Harmony Medicare Private Limited % ・Standalone data |
|
| Acquired Ownership Stake - Parekhs Hospital Private Limited % ・Standalone data |
|
| Acquired Ownership Stake - Patel Multispeciality Hospital and ICU % ・Standalone data |
|
| Acquired Ownership Stake - Patel Pharmacy % ・Standalone data |
|
| Acquisition Cost - Ashwini Medical Centre INR ・Standalone data |
|
| Acquisition Cost - Harmony Medicare Private Limited INR ・Standalone data |
|
| Acquisition Cost - Parekhs Hospital Private Limited INR ・Standalone data |
|
| Acquisition Cost - Patel Multispeciality Hospital and ICU INR ・Standalone data |
|
| Acquisition Cost - Patel Pharmacy INR ・Standalone data |
Extracted by Screener AI
Documents
Announcements
-
Format of the Initial Disclosure to be made by an entity identified as a Large Corporate : Annexure A
30 Apr - Company filed initial large corporate disclosure; outstanding borrowing was Rs 1.23 crore and not a large corporate.
-
Announcement under Regulation 30 (LODR)-Acquisition
27 Apr - Board approved new Company Secretary and WOS incorporation for healthcare expansion in Bharuch, effective 27 April 2026.
-
Appointment of Company Secretary and Compliance Officer
27 Apr - Board approved new Company Secretary, 100% WOS incorporation, and noted shareholder approvals on April 27, 2026.
-
Shareholder Meeting / Postal Ballot-Outcome of Postal_Ballot
25 Apr - Postal ballot passed three resolutions, including healthcare expansion fund use and financial statement revision.
-
Shareholder Meeting / Postal Ballot-Scrutinizer"s Report
25 Apr - Postal ballot on 25 Apr 2026 passed three resolutions, including fund utilisation, financial statement revision, and secretarial auditor appointment.
Annual reports
No data available.
Business Profile[1]
Gujarat Kidney and Super Speciality Limited is a regional healthcare operator in central Gujarat, running a chain of mid-sized multi-speciality hospitals focused on secondary and tertiary care.